Institute of Human Virology,
School of Medicine,
Institute of Human Virology, School of Medicine
Alonso Heredia has not added Biography.
If you are Alonso Heredia and would like to personalize this page please email our Author Liaison for assistance.
Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.
Proceedings of the National Academy of Sciences of the United States of America Apr, 2003 | Pubmed ID: 12644703
Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting.
Organic & biomolecular chemistry Mar, 2004 | Pubmed ID: 14985805
Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.
Bioconjugate chemistry Jul-Aug, 2004 | Pubmed ID: 15264865
Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity.
Journal of pharmaceutical sciences Oct, 2004 | Pubmed ID: 15349955
Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120.
Organic & biomolecular chemistry May, 2005 | Pubmed ID: 15858664
In vitro suppression of latent HIV-1 activation by vitamin E: potential clinical implications.
AIDS (London, England) May, 2005 | Pubmed ID: 15867501
Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication.
AIDS (London, England) Dec, 2005 | Pubmed ID: 16284457
HIV-1 natural viral suppressors: control of viral replication in the absence of therapy.
AIDS (London, England) Feb, 2007 | Pubmed ID: 17301571
Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
Antimicrobial agents and chemotherapy Jul, 2007 | Pubmed ID: 17485501
CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.
AIDS (London, England) Jun, 2007 | Pubmed ID: 17545708
Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment.
AIDS (London, England) Oct, 2007 | Pubmed ID: 17885304
An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.
Journal of virology Jun, 2008 | Pubmed ID: 18353949
Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2008 | Pubmed ID: 19075241
Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues.
Chembiochem : a European journal of chemical biology May, 2009 | Pubmed ID: 19353609
Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
Antiviral research Jul, 2009 | Pubmed ID: 19501260
Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.
Clinical medicine. Therapeutics , 2009 | Pubmed ID: 19920876
CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
Virology Mar, 2011 | Pubmed ID: 21232779
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
AIDS (London, England) Jun, 2011 | Pubmed ID: 21505306
Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.
The Journal of infectious diseases Dec, 2013 | Pubmed ID: 23922365
Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1.
AIDS (London, England) Jan, 2014 | Pubmed ID: 24326355
Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV.
AIDS research and human retroviruses May, 2014 | Pubmed ID: 24401082
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
Antiviral research Dec, 2014 | Pubmed ID: 25453341
Impact of HIV on lung tumorigenesis in an animal model.
AIDS (London, England) Mar, 2015 | Pubmed ID: 25611150
Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.
Proceedings of the National Academy of Sciences of the United States of America Jul, 2015 | Pubmed ID: 26170311
Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Current HIV research , 2016 | Pubmed ID: 26354735
A novel small-molecule inhibitor of HIV-1 entry.
Drug design, development and therapy , 2015 | Pubmed ID: 26491257
Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.
The Journal of antimicrobial chemotherapy 09, 2017 | Pubmed ID: 28637235
Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.
PloS one , 2017 | Pubmed ID: 28817720
Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients.
Antiviral therapy , 2019 | Pubmed ID: 30574873
Role of the inflammasomes in HIV-associated neuroinflammation and neurocognitive disorders.
Experimental and molecular pathology Jun, 2019 | Pubmed ID: 30922769
Suppression of Active HIV-1 Infection in CD34 Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.
AIDS research and human retroviruses Aug, 2019 | Pubmed ID: 31099257
CCR5 Inhibitors and HIV-1 Infection.
Journal of AIDS and HIV treatment , 2019 | Pubmed ID: 31414081
Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.
The Journal of clinical investigation Nov, 2019 | Pubmed ID: 31589168
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유